Harm-Jan Borgeld

Shanghai, China
Harm-Jan Borgeld is leading Roche’s Pharma Partnering team in Asia. He is based in Shanghai. The Asia Partnering team is responsible for seeking and executing global partnerships with exciting biotechs and pharma companies working on first in class and best in disease therapies in Japan, China, and South-Korea. Roche Asia Partnering is an integral component of the global Pharma Partnering unit, a team consisting of 120 people based across the globe who are looking for and maintaining lasting partnerships for Roche and Genentech’s R&D unit as well as the broader late-stage pharma division.
Prior to joining Roche, Harm-Jan led the Global Alliance Management Department at Merck Healthcare KGaA. Before heading the Global Alliance Management Department, he was leading a project team that worked on developing a novel immunotherapy to treat NSCLC and CRC. He started his work at Merck KGaA in the licensing and business development department. Prior to Merck, he was responsible for Business Development in Europe for the Japanese firm, Kyorin Pharmaceuticals. He received his MBA from the Rotterdam School of Management, the Netherlands / Haas Business School, US, and his PhD from the Faculty of Medicine, University of Nagoya, Japan, and graduated from the Wageningen University, the Netherlands.
Speaking In
10:45 AM - 12:00 PM (PDT)
Monday, June 13
Partnering activity in China continued to accelerate in 2021 with 658 deals generating a record $42…